Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases

Vaccine

Volumn 25, Issue 17, 2007, Pages 3338-3346

  Shi, Frank F ^a   Gunn, George R ^a   Snyder, Linda A ^a   Goletz, Theresa J ^a  

^a CENTOCOR INC   (United States)

Author keywords

DNA vaccine; IL 18; Immunotherapy; MUC1; Transgenic; Tumor

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 18; MUCIN 1; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; IMMUNIZATION; IMMUNOTHERAPY; LUNG METASTASIS; LUNG TUMOR; LYMPHOCYTE DEPLETION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR IMMUNITY; VACCINATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; CA-15-3 ANTIGEN; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; INTERFERON TYPE II; INTERLEUKIN-18; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; VACCINATION; VACCINES, DNA;

EID: 34047138021     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.007     Document Type: Article

References (48)

1. Gendler S.J., and Spicer A.P. Epithelial mucin genes. Annu Rev Physiol 57 (1995) 607-634
2. Girling A., Bartkova J., Burchell J., Gendler S., Gillett C., and Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 43 6 (1989) 1072-1076
3. Ho S.B., Niehans G.A., Lyftogt C., Yan P.S., Cherwitz D.L., Gum E.T., et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 53 3 (1993) 641-651
4. Agrawal B., Gendler S.J., and Longenecker B.M. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol Med Today 4 9 (1998) 397-403
5. Kotera Y., Fontenot J.D., Pecher G., Metzgar R.S., and Finn O.J. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54 11 (1994) 2856-2860
6. Barnd D.L., Lan M.S., Metzgar R.S., and Finn O.J. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86 18 (1989) 7159-7163
7. Finn O.J. Antigen-specific, MHC-unrestricted T cells. Biotherapy 4 4 (1992) 239-249
8. Domenech N., Henderson R.A., and Finn O.J. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 155 10 (1995) 4766-4774
9. Brossart P., Heinrich K.S., Stuhler G., Behnke L., Reichardt V.L., Stevanovic S., et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93 12 (1999) 4309-4317
10. Heukamp L.C., van der Burg S.H., Drijfhout J.W., Melief C.J., Taylor-Papadimitriou J., and Offringa R. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. Int J Cancer 91 3 (2001) 385-392
11. Zhang S., Graeber L.A., Helling F., Raqupathi G., Adluri S., Lloud K.O., et al. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res 56 14 (1996) 3315-3319
12. Soares M.M., Mehta V., and Finn O.J. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 166 11 (2001) 6555-6563
13. Acres B., Apostolopoulos V., Balloul J.M., Wreschner D., Xing P.X., Ali-Hadji D., et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 48 10 (2000) 588-594
14. Mushenkova N., Moiseeva E., Chaadaeva A., Den Otter W., and Svirshchevskaya E. Antitumor effect of double immunization of mice with mucin 1 and its coding DNA. Anticancer Res 25 6B (2005) 3893-3898
15. Scholl S.M., Balloul J.M., Le Goc G., Bizouarne N., Schatz C., Kieny M.P., et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 23 5 (2000) 570-580
16. Koido S., Kashiwaba M., Chen D., Gendler S., Kufe D., and Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 165 10 (2000) 5713-5719
17. Gong J., Chen D., Kashiwaba M., Li Y., Chen L., Takeuchi H., et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 95 11 (1998) 6279-6283
18. Chen D., Xia J., Tanaka Y., Chen H., Koido S., Wernet O., et al. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 109 2 (2003) 300-307
19. Graham R.A., Burchell J.M., Beverley P., and Taylor-Papadimitriou J. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 65 5 (1996) 664-670
20. Plunkett T., Graham R., Correa I., Sewell R., Miles D., Burchell J., et al. Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8 + and CD4 + T cells but does not require the MUC1 tandem repeat domain. Int J Cancer 109 5 (2004) 691-697
21. Snyder L.A., Goletz T.J., Gunn G.R., Shi F.F., Harris M.C., Cochlin K., et al. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine 24 16 (2006) 3340-3352
22. Peat N., Gendler S.J., Lalani N., Duhig T., and Taylor-Papadimitriou J. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res 52 7 (1992) 1954-1960
23. Fox B.A., Spiess P.J., Kasid A., Puri R., Mule J.J., Weber J.S., et al. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J Biol Response Mod 9 5 (1990) 499-511
24. Akagi J., Hodge J.W., McLaughlin J.P., Gritz L., Mazzara G., Kufe D., et al. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J Immunother 20 1 (1997) 38-47
25. Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst 36 4 (1966) 641-645
26. Dialynas D.P., Wilde D.B., Marrack P., Pierres A., Wall K.A., Havran W., et al. Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev 74 (1983) 29-56
27. Ledbetter J.A., and Herzenberg L.A. Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol Rev 47 (1979) 63-90
28. Kasai M., Iwamori M., Nagai Y., Okumura K., and Tada T. A glycolipid on the surface of mouse natural killer cells. Eur J Immunol 10 3 (1980) 175-180
29. Oshikawa K., Rakhmilevich A.L., Shi F., Sondel P.M., Yang N., and Mahvi D.M. Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer. Hum Gene Ther 12 2 (2001) 149-160
30. Gong J., Chen D., Kashiwaba M., and Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3 5 (1997) 558-561
31. Tempero R.M., VanLith M.L., Morikane K., Rowse G.J., Gendler S.J., and Hollingsworth M.A. CD4 + lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J Immunol 161 10 (1998) 5500-5506
32. Mukherjee P., Ginardi A.R., Madsen C.S., Sterner C.J., Adriance M.C., Tevethia M.J., et al. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J Immunol 165 6 (2000) 3451-3460
33. Reddish M., MacLean G.D., Koganty R.R., Kan-Mitchell J., Jones V., Mitchell M.S., et al. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 76 6 (1998) 817-823
34. Goydos J.S., Elder E., Whiteside T.L., Finn O.J., and Lotze M.T. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63 1 (1996) 298-304
35. Micallef M.J., Yoshida K., Kawai S., Hanaya T., Kohno K., Arai S., et al. In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 43 6 (1997) 361-367
36. Osaki T., Peron J.M., Cai Q., Okamura H., Robbins P.D., Kurimoto M., et al. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol 160 4 (1998) 1742-1749
37. Tatsumi T., Gambotto A., Robbins P.D., and Storkus W.J. Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. Cancer Res 62 20 (2002) 5853-5858
38. Lowes M.A., Bishop G.A., Crotty K., Barnetson R.S., and Halliday G.M. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol 108 6 (1997) 914-919
39. Kremer L., Dupre L., Wolowczuk I., and Locht C. In vivo immunomodulation following intradermal injection with DNA encoding IL-18. J Immunol 163 6 (1999) 3226-3231
40. Kaser A., Kaser S., Kaneider N.C., Enrich B., Wiedermann C.J., and Tilg H. Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood 103 2 (2004) 648-655
41. Komai-Koma M., Gracie J.A., Wei X.Q., Xu D., Thomson N., McInnes I.B., et al. Chemoattraction of human T cells by IL-18. J Immunol 170 2 (2003) 1084-1090
42. Cumberbatch M., Dearman R.J., Antonopoulos C., Groves R.W., and Kimber I. Interleukin (IL)-18 induces Langerhans cell migration by a tumour necrosis factor-alpha- and IL-1beta-dependent mechanism. Immunology 102 3 (2001) 323-330
43. Tempero R.M., Rowse G.J., Gendler S.J., and Hollingsworth M.A. Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice. Int J Cancer 80 4 (1999) 595-599
44. Boehm U., Klamp T., Groot M., and Howard J.C. Cellular responses to interferon-gamma. Annu Rev Immunol 15 (1997) 749-795
45. Revel M., and Chebath J. Interferon-activated genes. Trends Biochem Sci 11 4 (1986) 166-170
46. Coughlin C.M., Salhany K.E., Wysocka M., Aruga E., Kurzawa H., Chang A.E., et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101 6 (1998) 1441-1452
47. Oshikawa K., Shi F., Rakhmilevich A.L., Sondel P.M., Mahvi D.M., and Yang N.S. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA. Proc Natl Acad Sci USA 96 23 (1999) 13351-13356
48. Baxevanis C.N., Gritzapis A.D., and Papamichail M. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18. J Immunol 171 6 (2003) 2953-2959